Currently, a phase III trial comparing SHR-A1811 vs. SoC (camrelizumab + pemetrexed/paclitaxel + carboplatin/cisplatin) in first-line HER2 MUT NSCLC is ongoing in China (NCT06430437). Here, ERBB2 is linked to non-small cell lung carcinoma.